Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

References

• Gottesman MM. Mechanisms of cancer drug resistance. Annu. Rev. Med.53, 615–627 (2002).
   PubMed Web of Science ®Google Scholar
• Mattern J. Drug resistance in cancer: a multifactorial problem. Anticancer Res.23(2C), 1769–1772 (2003).
   PubMed Web of Science ®Google Scholar
• Yague E, Raguz S. Drug resistance in cancer. Br. J. Cancer93(9), 973–976 (2005).
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res.11(7), 1156–1166 (2001).
   PubMed Web of Science ®Google Scholar
• Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets7(7), 893–909 (2006).
   PubMed Web of Science ®Google Scholar
• Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev.86(4), 1179–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta455(1), 152–62 (1976).
   PubMed Web of Science ®Google Scholar
• Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl Acad. Sci. USA84(1), 265–269 (1987).
   PubMed Web of Science ®Google Scholar
• Linn SC, Pinedo HM, van Ark-Otte J et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int. J. Cancer71(5), 787–795 (1997).
   PubMed Web of Science ®Google Scholar
• Bates SE, Mickley LA, Chen YN et al. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol. Cell. Biol.9(10), 4337–4344 (1989).
   PubMed Web of Science ®Google Scholar
• Sandor V, Wilson W, Fojo T, Bates SE. The role of MDR-1 in refractory lymphoma. Leuk. Lymphoma28(1–2), 23–31 (1997).
   PubMed Web of Science ®Google Scholar
• Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A, Cerny T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol. Oncol.70(2), 176–182 (1998).
   PubMed Web of Science ®Google Scholar
• Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer36(7), 881–888 (2000).
   PubMed Web of Science ®Google Scholar
• Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br. J. Haematol.128(3), 324–332 (2005).
   PubMed Web of Science ®Google Scholar
• Raspadori D, Damiani D, Michieli M et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica87(11), 1135–1140 (2002).
   PubMed Web of Science ®Google Scholar
• Senent L, Jarque I, Martin G et al. P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica83(9), 783–787 (1998).
   PubMed Web of Science ®Google Scholar
• Hunault M, Zhou D, Delmer A et al. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann. Hematol.74(2), 65–71 (1997).
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PA et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br. J. Haematol.99(1), 76–83 (1997).
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood97(11), 3605–3611 (2001).
   PubMed Web of Science ®Google Scholar
• Wood P, Burgess R, MacGregor A, Yin JA. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br. J. Haematol.87(3), 509–514 (1994).
   PubMed Web of Science ®Google Scholar
• Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk. Lymphoma43(6), 1221–1228 (2002).
   PubMed Web of Science ®Google Scholar
• List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia10(6), 937–942 (1996).
   PubMed Web of Science ®Google Scholar
• Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia14(3), 467–473 (2000).
   PubMed Web of Science ®Google Scholar
• Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene22(47), 7512–7523 (2003).
   PubMed Web of Science ®Google Scholar
• Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found. Symp.243, 83–96; Discussion 102, 80–85 (2002).
   PubMedGoogle Scholar
• Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev.42(3), 155–199 (1990).
   PubMed Web of Science ®Google Scholar
• Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res.59(16), 3944–3948 (1999).
   PubMed Web of Science ®Google Scholar
• Fischer V, Rodriguez-Gascon A, Heitz F et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug–drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos.26(8), 802–811 (1998).
   PubMed Web of Science ®Google Scholar
• Boote DJ, Dennis IF, Twentyman PR et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol.14(2), 610–618 (1996).
   PubMed Web of Science ®Google Scholar
• Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control10(2), 159–165 (2003).
   PubMedGoogle Scholar
• Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol.128(2), 403–411 (1999).
   PubMed Web of Science ®Google Scholar
• Roe M, Folkes A, Ashworth P et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett.9(4), 595–600 (1999).
   PubMed Web of Science ®Google Scholar
• Globisch C, Pajeva IK, Wiese M. Structure–activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg. Med. Chem.14(5), 1588–1598 (2006).
   PubMed Web of Science ®Google Scholar
• Mistry P, Stewart AJ, Dangerfield W et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res.61(2), 749–758 (2001).
   PubMed Web of Science ®Google Scholar
• Walker J, Martin C, Callaghan R. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur. J. Cancer40(4), 594–605 (2004).
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O et al. Pheophorbide A is a specific probe for ABCG2 function and inhibition. Cancer Res.64(4), 1242–1246 (2004).
   PubMed Web of Science ®Google Scholar
• Robey R, Bakke S, Stein W et al. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood93(1), 306–314 (1999).
   PubMed Web of Science ®Google Scholar
• Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin. Cancer Res.6(11), 4186–4191 (2000).
   PubMed Web of Science ®Google Scholar
• Abraham J, Edgerly M, Wilson R et al. Phase I study of the novel P-glycoprotein antagonist, XR9576, in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol.20, 73A (2001) (Abstract 287).
   Web of Science ®Google Scholar
• Fox E, Widemann BC, Chen CC et al. Pediatric Phase I trial and pharmcokinetic study of the P-glycoprotien inhibitor, tariquidar, in combination with doxorubicin, vinorelbine, or docetaxel. Proc. Am. Soc. Clin. Oncol.22(Suppl. 14), S809 (2004) (Abstract 8541).
   Google Scholar
• Pinwnica-Worms D. Functional identification of multidrug resistance gene expression in vivo. Lippincott Williams & Wilkins, LA, USA (2000).
   Google Scholar
• Agrawal M, Abraham J, Balis FM et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res.9(2), 650–656 (2003).
   PubMed Web of Science ®Google Scholar
• Boniface G, Ferry D, Atsmon J et al. XR9576 (tariquidar) a potent and specific P-glycoprotien inhibitor has minimal effects on the pharmacokinetics of paclitaxel, doxorubicin, and vinorelbine, and can be administered with full-dose chemotherapy in patients with cancer. Proc. Am. Soc. Clin. Oncol.21, 90B (2002) (Abstract 2173).
   Google Scholar
• Pusztal L, Wagner P, Ibrahim N et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer104(4), 682–691 (2005).
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets7(7), 861–879 (2006).
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Sparreboom A, van der Gaast A et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res.6(4), 1365–1371 (2000).
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest. New Drugs22(3), 219–229 (2004).
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Bosch TM, van Maanen MJ et al. Oral bioavailability of docetaxel in combination with OC144–093 (ONT-093). Cancer Chemother. Pharmacol.55(1), 72–78 (2005).
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Ouwehand M, Buckle T et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res.62(21), 6158–6164 (2002).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gordon M, De Alwis DP et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin. Cancer Res.10(10), 3265–3272 (2004).
   PubMed Web of Science ®Google Scholar
• Bates S, Kang M, Meadows B et al. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer92(6), 1577–1590 (2001).
   PubMed Web of Science ®Google Scholar
• Visani G, Milligan D, Leoni F et al. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia15(5), 764–771 (2001).
   PubMed Web of Science ®Google Scholar
• Advani R, Lum BL, Fisher GA et al. A Phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Ann. Oncol.16(12), 1968–1973 (2005).
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Blum KA, Ma MK et al. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br. J. Cancer93(1), 46–53 (2005).
   PubMed Web of Science ®Google Scholar
• Chen J, Balmaceda C, Bruce JN et al. Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J. Neurooncol.76(1), 85–92 (2006).
   PubMed Web of Science ®Google Scholar
• Nuessler V, Scheulen ME, Oberneder R et al. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. Eur. J. Med. Res.2(2), 55–61 (1997).
   PubMedGoogle Scholar
• Rubin EH, de Alwis DP, Pouliquen I et al. A Phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin. Cancer Res.8(12), 3710–3717 (2002).
   PubMed Web of Science ®Google Scholar
• Le LH, Moore MJ, Siu LL et al. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother. Pharmacol.56(2), 154–160 (2005).
   PubMed Web of Science ®Google Scholar
• Gerrand G, Payne E, Baker RJ et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin, and cytarabine. Haematologica89, 782–790 (2004).
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Lee SJ, Advani R et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase III trial (E2995). J. Clin. Oncol.22(6), 1078–1086 (2004).
   PubMed Web of Science ®Google Scholar
• Chico I, Kang MH, Bergan R et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J. Clin. Oncol.19(3), 832–842 (2001).
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Brady MF, Moore DH et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol.19(12), 2975–2982 (2001).
   PubMed Web of Science ®Google Scholar
• Volm M, Koomagi R, Mattern J, Efferth T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br. J. Cancer87(3), 251–257 (2002).
   PubMed Web of Science ®Google Scholar
• Berger W, Setinek U, Hollaus P et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J. Cancer Res. Clin. Oncol.131(6), 355–363 (2005).
   PubMed Web of Science ®Google Scholar
• Oka M, Fukuda M, Sakamoto A et al. The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res.17(1B), 721–724 (1997).
   PubMed Web of Science ®Google Scholar
• Shin HJ, Lee JS, Hong WK, Shin DM. Study of multidrug resistance (Mdr1) gene in non-small-cell lung cancer. Anticancer Res.12(2), 367–370 (1992).
   PubMed Web of Science ®Google Scholar
• Wishart GC, Bissett D, Paul J et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. Clin. Oncol.12(9), 1771–1777 (1994).
   PubMed Web of Science ®Google Scholar
• Wattel E, Solary E, Hecquet B et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br. J. Haematol.102(4), 1015–1024 (1998).
   PubMed Web of Science ®Google Scholar
• Wattel E, Solary E, Hecquet B et al. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS. Adv. Exp. Med. Biol.457, 35–46 (1999).
   PubMed Web of Science ®Google Scholar
• Solary E, Witz B, Caillot D et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood88(4), 1198–1205 (1996).
   PubMed Web of Science ®Google Scholar
• Solary E, Drenou B, Campos L et al. Quinine as a multidrug resistance inhibitor: a Phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood102(4), 1202–1210 (2003).
   PubMed Web of Science ®Google Scholar
• Wood L. Results of a Phase III double blind placebo controlled trial of megestrol acetate modulation of P-glycoprotein mediated drug resistance in the first line management of small cell lung carcinoma. Br. J. Cancer77, 627–631 (1998).
   PubMed Web of Science ®Google Scholar
• Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br. J. Cancer67(5), 1031–1035 (1993).
   PubMed Web of Science ®Google Scholar
• Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br. J. Cancer68(4), 813–818 (1993).
   PubMed Web of Science ®Google Scholar
• Dalton WS, Crowley JJ, Salmon SS et al. A Phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer75(3), 815–820 (1995).
   PubMed Web of Science ®Google Scholar
• Belpomme D, Gauthier S, Pujade-Lauraine E et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol.11(11), 1471–1476 (2000).
   PubMed Web of Science ®Google Scholar
• Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br. J. Haematol.113(3), 713–726 (2001).
   PubMed Web of Science ®Google Scholar
• List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood98(12), 3212–3220 (2001).
   PubMed Web of Science ®Google Scholar
• Baldus C, Fietz T, Rieder H, Schwartz S, Thiel E, Knauf W. MDR-1 expression and deletions of chromosomes 7 and 5(Q) separately indicate adverse prognosis in AML. Leuk. Lymphoma40(5–6), 613–623 (2001).
   PubMed Web of Science ®Google Scholar
• van der Holt B, Lowenberg B, Burnett AK et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood106(8), 2646–2654 (2005).
   PubMed Web of Science ®Google Scholar
• Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood100(4), 1224–1232 (2002).
   PubMed Web of Science ®Google Scholar
• Kolitz JE, George SL, Dodge RK et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J. Clin. Oncol.22(21), 4290–4301 (2004).
   PubMed Web of Science ®Google Scholar
• Joly F et al. A Phase 3 study of PSC833 in combination with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol.21, (2002) (Abstract 806).
   Google Scholar
• Robert J. MS-209 Schering. Curr. Opin. Investig. Drugs5(12), 1340–1347 (2004).
   PubMedGoogle Scholar
• Abraham J, Bakke S, Rutt A et al. A Phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer94(9), 2333–2343 (2002).
   PubMed Web of Science ®Google Scholar
• Kemper EM, van Zandbergen AE, Cleypool C et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin. Cancer Res.9(7), 2849–2855 (2003).
   PubMed Web of Science ®Google Scholar
• Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother. Pharmacol.53(2), 173–178 (2004).
   PubMed Web of Science ®Google Scholar
• Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem.67(4), 1688–1693 (1996).
   PubMed Web of Science ®Google Scholar
• Warren KE, Patel MC, McCully CM, Montuenga LM, Balis FM. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Cancer Chemother. Pharmacol.45(3), 207–212 (2000).
   PubMed Web of Science ®Google Scholar
• Hughes CS, Vaden SL, Manaugh CA, Price GS, Hudson LC. Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J. Neurooncol.37(1), 45–54 (1998).
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther.301(1), 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett.327(3), 173–176 (2002).
   PubMed Web of Science ®Google Scholar
• Potschka H, Loscher W. A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats. Neuroreport13(1), 167–171 (2002).
   PubMed Web of Science ®Google Scholar
• van Vliet EA, van Schaik R, Edelbroek PM et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia47(4), 672–680 (2006).
   PubMed Web of Science ®Google Scholar
• Brandt C, Bethmann K, Gastens AM, Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis.24(1), 202–211 (2006).
   PubMed Web of Science ®Google Scholar
• Choo EF, Leake B, Wandel C et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos.28(6), 655–660 (2000).
   PubMed Web of Science ®Google Scholar
• Imbert F, Jardin M, Fernandez C et al. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.Drug Metab. Dispos.31(3), 319–325 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards JE, Brouwer KR, McNamara PJ. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob. Agents Chemother.46(7), 2284–2286 (2002).
   PubMed Web of Science ®Google Scholar
• Savolainen J, Edwards JE, Morgan ME, McNamara PJ, Anderson BD. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab. Dispos.30(5), 479–482 (2002).
   PubMed Web of Science ®Google Scholar
• Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther.68(3), 231–237 (2000).
   PubMed Web of Science ®Google Scholar
• Choo EF, Kurnik D, Muszkat M et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood–brain barrier. J. Pharmacol. Exp. Ther.317(3), 1012–1018 (2006).
   PubMed Web of Science ®Google Scholar
• Lotsch J, Schmidt R, Vetter G et al. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J. Neurochem.83(2), 241–248 (2002).
   PubMed Web of Science ®Google Scholar
• Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood–brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest.100(10), 2430–2436 (1997).
   PubMed Web of Science ®Google Scholar
• Karssen AM, Meijer OC, van der Sandt IC, De Boer AG, De Lange EC, De Kloet ER. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol.175(1), 251–260 (2002).
   PubMed Web of Science ®Google Scholar
• Karssen AM, Meijer OC, van der Sandt IC et al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology142(6), 2686–2694 (2001).
   PubMed Web of Science ®Google Scholar
• Marchi N, Guiso G, Caccia S et al. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. Neurobiol. Dis.24(3), 429–442 (2006).
   PubMed Web of Science ®Google Scholar